• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int Immunopharmacol . Novel serological biomarkers for inflammation in predicting disease severity in patients with COVID-19

tetano

Editor, Senior Moderator
Int Immunopharmacol


. 2020 Oct 3;89(Pt A):107065.
doi: 10.1016/j.intimp.2020.107065. Online ahead of print.
Novel serological biomarkers for inflammation in predicting disease severity in patients with COVID-19


Guohui Xue[SUP] 1 [/SUP], Xing Gan[SUP] 2 [/SUP], Zhiqiang Wu[SUP] 2 [/SUP], Dan Xie[SUP] 3 [/SUP], Yan Xiong[SUP] 2 [/SUP], Lin Hua[SUP] 4 [/SUP], Bing Zhou[SUP] 5 [/SUP], Nanjin Zhou[SUP] 6 [/SUP], Jie Xiang[SUP] 7 [/SUP], Junming Li[SUP] 8 [/SUP]



Affiliations

Abstract

Background: Patients with severe coronavirus disease 2019 (COVID-19) develop acute respiratory distress and multi-system organ failure and are associated with poor prognosis and high mortality. Thus, there is an urgent need to identify early diagnostic and prognostic biomarkers to determine the risk of developing serious illness.
Methods: We retrospectively analyzed 114 patients with COVID-19 at the Jinyintan Hospital, Wuhan based on their clinical and laboratory data. Patients were categorized into severe and mild to moderate disease groups. We analyzed the potential of serological inflammation indicators in predicting the severity of COVID-19 in patients using univariate and multivariate logistic regression, receiver operating characteristic curves, and nomogram analysis. The Spearman method was used to understand the correlation between the serological biomarkers and duration of hospital stay.
Results: Patients with severe disease had reduced neutrophils and lymphocytes; severe coagulation dysfunction; altered content of biochemical factors (such as urea, lactate dehydrogenase); elevated high sensitivity C-reactive protein levels, neutrophil-lymphocyte, platelet-lymphocyte, and derived neutrophil-lymphocyte ratios, high sensitivity C-reactive protein-prealbumin ratio (HsCPAR), systemic immune-inflammation index, and high sensitivity C-reactive protein-albumin ratio (HsCAR); and low lymphocyte-monocyte ratio, prognostic nutritional index (PNI), and albumin-to-fibrinogen ratio. PNI, HsCAR, and HsCPAR correlated with the risk of severe disease. The nomogram combining the three parameters showed good discrimination with a C-index of 0.873 and reliable calibration. Moreover, HsCAR and HsCPAR correlated with duration of hospital stay.
Conclusion: Taken together, PNI, HsCAR, and HsCPAR may serve as accurate biomarkers for the prediction of disease severity in patients with COVID-19 upon admission/hospitalization.

Keywords: COVID-19; High sensitivity C-reactive protein-albumin ratio; High sensitivity C-reactive protein-prealbumin ratio; Nomogram; Prognostic nutritional index; Severity.
 
Back
Top Bottom